February 2026—Diasorin has received FDA 510(k) clearance and CLIA waiver for its first assay, a flu A/B, RSV, and COVID-19 panel, to be used on the Liaison Nes point-of-care molecular diagnostic platform. Features of the Liaison Nes include an integrated barcode reader, wireless operation, ready-to-use cartridges, and room-temperature consumables. Results are available in about 15 minutes.
Diasorin, 651-439-9710